Strongbridge Biopharma Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Strongbridge Biopharma stock.
View analyst ratings for Strongbridge Biopharma or view top-rated stocks.

Wall Street analysts have given Strongbridge Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Strongbridge Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Strongbridge Biopharma.

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its quarterly earnings data on Tuesday, March, 2nd. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 65.85% and a negative net margin of 149.79%.
View Strongbridge Biopharma's earnings history.

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SBBP shares have increased by 19.8% and is now trading at $2.78.
View which stocks have been most impacted by COVID-19.

Strongbridge Biopharma updated its FY 2021 Pre-Market earnings guidance on Wednesday, March, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $34-36 million, compared to the consensus revenue estimate of $35.81 million.

3 brokerages have issued 12-month price targets for Strongbridge Biopharma's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 151.8% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Strongbridge Biopharma include Chinook Therapeutics (KDNY), Provention Bio (PRVB), Gossamer Bio (GOSS), Merus (MRUS), Dyne Therapeutics (DYN), Xenon Pharmaceuticals (XENE), Calliditas Therapeutics AB (publ) (CALT), Odonate Therapeutics (ODT), Intercept Pharmaceuticals (ICPT), Emisphere Technologies (EMIS), Atreca (BCEL), Albireo Pharma (ALBO), Rigel Pharmaceuticals (RIGL), BELLUS Health (BLUSF) and Magenta Therapeutics (MGTA).
View all of SBBP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB).

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (3.63%), Renaissance Technologies LLC (3.26%), BlackRock Inc. (3.14%), Morgan Stanley (2.90%), Stonepine Capital Management LLC (2.01%) and Hudson Bay Capital Management LP (1.90%). Company insiders that own Strongbridge Biopharma stock include Associates LLC Cdk and David N Gill.
View institutional ownership trends for Strongbridge Biopharma.

SBBP stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and Stonepine Capital Management LLC.
View insider buying and selling activity for Strongbridge Biopharma or view top insider-selling stocks.

SBBP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Worth Venture Partners LLC, BlackRock Inc., JPMorgan Chase & Co., Bank of New York Mellon Corp, Northern Trust Corp, Principal Financial Group Inc., and Morgan Stanley. Company insiders that have bought Strongbridge Biopharma stock in the last two years include Associates LLC Cdk, and David N Gill.
View insider buying and selling activity for Strongbridge Biopharma or or view top insider-buying stocks.

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SBBP stock can currently be purchased for approximately $2.78.

Strongbridge Biopharma has a market capitalization of $186.94 million and generates $21.71 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.

Strongbridge Biopharma employs 71 workers across the globe.

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

Strongbridge Biopharma is headquartered at 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]